Maternal Serum Copeptin As a Biomarker For Intrauterine Growth Restriction: Serum Copeptin As a Biomarker For IUGR

Amber Hassan; Hisham  Nasief

doi:10.54393/pbmj.v4i2.78

Authors

Amber Hassan Department of System Medicine, Ceinge Biotechnologie Avanzate S.C.R.L. University of Naples Federico II, Naples, Italy
Hisham Nasief Department of Obstetric and Gynecology, Faculty of Medicine, King Abdul Aziz University and Hospital, Jeddah, Saudi Arabia

DOI:

https://doi.org/10.54393/pbmj.v4i2.78

Abstract

In obstetrical world, Intrauterine Growth Restriction (IUGR) occupies second slot as a cause of small for gestation neonates, first being premature birth, both of which result in potential neonatal morbidities and mortalities. IUGR is defined as an estimated fetal weight at one point in time at or below 10^th percentile for gestational age. Annually about thirty million babies suffer from IUGR and out of these about 75% are Asians. IUGR has been found to be associated with increased levels of Copeptin. As copeptin is a marker of endogenous stress, so increased copeptin levels can indicate fetal and maternal stress in IUGR

Objectives: The objectives of this study were to the compare maternal serum copeptin levels in pregnancies with IUGR and pregnancies with adequate for gestational age fetuses and to establish the significance of copeptin as a biomarker for IUGR.

Methodology: It was a cross-sectional comparative study in which maternal serum copeptin levels were measured and compared in 60 patients divided in two groups, pregnancies with IUGR and normal pregnancies with adequate for gestation age fetuses between 28-35 weeks of gestation

Results: Maternal serum copeptin levels were raised in pregnant women with IUGR as compared to that in pregnant women with adequate for gestational age fetuses. Mean ± SD maternal serum copeptin levels were 97.5 ± 6 pg/ml in pregnant women with AGA fetuses and 121 ± 7.8 pg/ml in pregnant women with IUGR.

Conclusions: Maternal serum copeptin levels are raised in pregnancies with IUGR as compared to pregnancies with adequate for age fetuses which can represent as a possible clinical biomarker for identification of IUGR.

References

Tabet M, Flick L, Xian H, Chang J. Revisiting the low birthweight paradox using sibling data with implications for the classification of low birthweight. J. Pub. Hlth. 2018; 40(4): e601-e7. doi: 10.1093/pubmed/fdy087

Prajapati R, Shrestha S, Bhandari N. Prevalence and Associated Factors of Low Birth Weight among Newborns in a Tertiary Level Hospital in Nepal. Kathmandu Univ. Med J 2018; 61(1): 49-52. https://pubmed.ncbi.nlm.nih.gov/30631017/

Gimenez LG, Krupitzki HB, Momany AM, et al. Maternal and neonatal epidemiological features in clinical subtypes of preterm birth. J. Matern.-Fetal Neonatal Med. 2016; 29(19): 3153-61. doi: 10.3109/14767058.2015.1118035

Chawanpaiboon S, Vogel JP, Moller A-B, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. The Lancet Global Health 2019; 7(1): e37-e46. doi: 10.1016/S2214-109X(18)30451-0

Nardozza LMM, Caetano ACR, Zamarian ACP, et al. Fetal growth restriction: current knowledge. Archives of gynecology and obstetrics 2017; 295(5): 1061-77. doi: 10.1007/s00404-017-4341-9

Shrestha A, Pradhan N, Kayastha B. Risk Factors for Intrauterine Growth Restriction: 9 Years Analysis in Tertiary Care Hospital. J. BP Koirala Inst. Hlth. Sci. 2019; 2(1): 77-82. doi:10.3126/jbpkihs.v2i1.24973

Vijayaselvi R, Cherian AG. Risk assessment of intrauterine growth restriction. Current Med. Iss. 2017; 15(4): 262. doi: 10.4103/cmi.cmi_76_17

Ernst SA, Brand T, Reeske A, Spallek J, Petersen K, Zeeb H. Care-related and maternal risk factors associated with the antenatal nondetection of intrauterine growth restriction: a case-control study from Bremen, Germany. BioMed research international 2017; 2017. doi: 10.1155/2017/1746146

Longo S, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J. Mater.-Fetal & Neonatal Med. 2013; 26(3): 222-5. doi: 10.3109/14767058.2012.715006

Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson's disease: advances and strategies. Parkinsonism & related disorders 2016; 22: S106-S10. doi: 10.1016/j.parkreldis.2015.09.048

Perovic E, Mrdjen A, Harapin M, Tesija Kuna A, Simundic A-M. Diagnostic and prognostic role of resistin and copeptin in acute ischemic stroke. Topics in stroke rehabilitation 2017; 24(8): 614-8. doi: 10.1080/10749357.2017.1367454

Amin DM. Role of copeptin as a novel biomarker of bisphenol A toxic effects on cardiac tissues: biochemical, histological, immunohistological, and genotoxic study. Envir. Sci. Pollu. Res. 2019; 26(35): 36037-47. doi: 10.1007/s11356-019-06855-8

Bolignano D, Cabassi A, Fiaccadori E, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clini. Chem. Lab. Med. (CCLM) 2014; 52(10): 1447-56. doi: 10.1515/cclm-2014-0379

Deng G, Perschbacher KJ, Sandgren JA, et al. Abstract P261: Vasopressin System Components are Dysregulated in Human Preeclamptic Placenta. Hypertension 2017; 70(suppl_1): AP261-AP. https://www.ahajournals.org/doi/10.1161/hyp.70.suppl_1.p261

Seikku L. Biomarkers of intrauterine hypoxia and perinatal asphyxia, and gestational age as predictors of neonatal outcome. 2020. https://helda.helsinki.fi/handle/10138/308922

Alizzi FJ, Bardan RM. Role of maternal serum copeptin in correlation with umbilical cord copeptin and umbilical artery Doppler indices in differentiating IUGR from constitutional small and appropriate for gestational age fetuses. J. Pharm. Sci. Res. 2018; 10(3): 597-600. http://jpsr.pharmainfo.in/Documents/Volumes/vol10Issue03/jpsr10031835.pdf

Menon S, Amanullah N. Maternal and neonatal determinants of neonatal jaundice–a case control study. J. Med. Sci. clin. Res. 2017; 5(03): 19659-65. doi:10.18535/jmscr/v5i3.210

Villela-Torres MDLL, Higareda-Mendoza AE, Gómez-García A, et al. Copeptin plasma levels are associated with decline of renal function in patients with type 2 diabetes mellitus. Arch. med. res. 2018; 49(1): 36-43. doi: 10.1016/j.arcmed.2018.04.002

Manandhar T, Prashad B, Nath Pal M. Risk Factors for Intrauterine Growth Restriction and Its Neonatal Outcome. Gynecol Obstet 2018; 8(464): 2161-0932.1000464. doi: 10.4172/2161-0932.1000464

Hajianfar H, Esmaillzadeh A, Feizi A, Shahshahan Z, Azadbakht L. Major maternal dietary patterns during early pregnancy and their association with neonatal anthropometric measurement. BioMed res. intern. 2018; 2018. doi: 10.1155/2018/4692193

Briana DD, Boutsikou M, Boutsikou T, Dodopoulos T, Gourgiotis D, Malamitsi-Puchner A. Plasma copeptin may not be a sensitive marker of perinatal stress in healthy full-term growth-restricted fetuses. J. Mater.-Fetal Neonatal Med. 2017; 30(6): 705-9. doi: 10.1080/14767058.2016.1183632

Beljan P, Elveđi-Gašparović V, Oguić SK, Radošević V, Schuster S, Škrablin S. Can first trimester placental biomarkers copeptin and PP13 predict preeclampsia in advanced age nulliparous women? Signa Vitae-A Journal In Intensive Care And Emergency Medicine 2017; 13(Suppl 3). doi:10.22514/SV133.062017.14